Fuan Pharmaceutical Group Co (300194) - Net Assets
Based on the latest financial reports, Fuan Pharmaceutical Group Co (300194) has net assets worth CN¥4.43 Billion CNY (≈ $647.58 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥5.63 Billion ≈ $824.31 Million USD) and total liabilities (CN¥1.21 Billion ≈ $176.74 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset allocation strategy of Fuan Pharmaceutical Group Co to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥4.43 Billion |
| % of Total Assets | 78.56% |
| Annual Growth Rate | 41.62% |
| 5-Year Change | 12.92% |
| 10-Year Change | 10.14% |
| Growth Volatility | 295.31 |
Fuan Pharmaceutical Group Co - Net Assets Trend (2007–2025)
This chart illustrates how Fuan Pharmaceutical Group Co's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market value of Fuan Pharmaceutical Group Co.
Annual Net Assets for Fuan Pharmaceutical Group Co (2007–2025)
The table below shows the annual net assets of Fuan Pharmaceutical Group Co from 2007 to 2025. Also explore net asset momentum of Fuan Pharmaceutical Group Co to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥4.37 Billion ≈ $638.81 Million |
-0.74% |
| 2024-12-31 | CN¥4.40 Billion ≈ $643.58 Million |
+6.01% |
| 2023-12-31 | CN¥4.15 Billion ≈ $607.09 Million |
+5.12% |
| 2022-12-31 | CN¥3.95 Billion ≈ $577.49 Million |
+2.09% |
| 2021-12-31 | CN¥3.87 Billion ≈ $565.70 Million |
-15.13% |
| 2020-12-31 | CN¥4.56 Billion ≈ $666.55 Million |
+14.18% |
| 2019-12-31 | CN¥3.99 Billion ≈ $583.77 Million |
+8.00% |
| 2018-12-31 | CN¥3.69 Billion ≈ $540.55 Million |
-11.43% |
| 2017-12-31 | CN¥4.17 Billion ≈ $610.29 Million |
+5.22% |
| 2016-12-31 | CN¥3.96 Billion ≈ $580.00 Million |
+85.55% |
| 2015-12-31 | CN¥2.14 Billion ≈ $312.59 Million |
+25.11% |
| 2014-12-31 | CN¥1.71 Billion ≈ $249.86 Million |
-1.01% |
| 2013-12-31 | CN¥1.72 Billion ≈ $252.41 Million |
+0.25% |
| 2012-12-31 | CN¥1.72 Billion ≈ $251.77 Million |
+1.66% |
| 2011-12-31 | CN¥1.69 Billion ≈ $247.66 Million |
+502.18% |
| 2010-12-31 | CN¥281.05 Million ≈ $41.13 Million |
+72.10% |
| 2009-12-31 | CN¥163.31 Million ≈ $23.90 Million |
+47.45% |
| 2008-12-31 | CN¥110.76 Million ≈ $16.21 Million |
+1232.49% |
| 2007-12-31 | CN¥8.31 Million ≈ $1.22 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Fuan Pharmaceutical Group Co's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 83365346593.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥833.44 Million | 19.10% |
| Other Components | CN¥3.53 Billion | 80.90% |
| Total Equity | CN¥4.36 Billion | 100.00% |
Fuan Pharmaceutical Group Co Competitors by Market Cap
The table below lists competitors of Fuan Pharmaceutical Group Co ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
DBAPPSecurity Co Ltd
SHG:688023
|
$658.16 Million |
|
Qian Jiang Water Resources Development Co Ltd
SHG:600283
|
$658.17 Million |
|
Zhejiang Xinao Textiles Inc
SHG:603889
|
$658.24 Million |
|
Sawit Sumbermas Sarana Tbk
JK:SSMS
|
$658.59 Million |
|
Kodiak AI, Inc. Common Stock
NASDAQ:KDK
|
$658.03 Million |
|
SimilarWeb Ltd
NYSE:SMWB
|
$657.88 Million |
|
Cubic Sensor and Instrument Co Ltd
SHG:688665
|
$657.75 Million |
|
Shenzhen Easttop Supply Chain Management Co Ltd
SHE:002889
|
$657.65 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Fuan Pharmaceutical Group Co's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,395,875,171 to 4,363,770,859, a change of -32,104,312 (-0.7%).
- Net income of 76,997,130 contributed positively to equity growth.
- Dividend payments of 104,990,903 reduced retained earnings.
- Other comprehensive income decreased equity by 139,207,177.
- Other factors increased equity by 135,096,638.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥77.00 Million | +1.76% |
| Dividends Paid | CN¥104.99 Million | -2.41% |
| Other Comprehensive Income | CN¥-139.21 Million | -3.19% |
| Other Changes | CN¥135.10 Million | +3.1% |
| Total Change | CN¥- | -0.73% |
Book Value vs Market Value Analysis
This analysis compares Fuan Pharmaceutical Group Co's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.03x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 7.85x to 1.03x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | CN¥0.48 | CN¥3.78 | x |
| 2008-12-31 | CN¥0.46 | CN¥3.78 | x |
| 2009-12-31 | CN¥0.27 | CN¥3.78 | x |
| 2010-12-31 | CN¥0.47 | CN¥3.78 | x |
| 2011-12-31 | CN¥2.26 | CN¥3.78 | x |
| 2012-12-31 | CN¥2.18 | CN¥3.78 | x |
| 2013-12-31 | CN¥2.18 | CN¥3.78 | x |
| 2014-12-31 | CN¥2.19 | CN¥3.78 | x |
| 2015-12-31 | CN¥2.61 | CN¥3.78 | x |
| 2016-12-31 | CN¥3.39 | CN¥3.78 | x |
| 2017-12-31 | CN¥3.51 | CN¥3.78 | x |
| 2018-12-31 | CN¥3.08 | CN¥3.78 | x |
| 2019-12-31 | CN¥3.41 | CN¥3.78 | x |
| 2020-12-31 | CN¥3.53 | CN¥3.78 | x |
| 2021-12-31 | CN¥3.14 | CN¥3.78 | x |
| 2022-12-31 | CN¥3.28 | CN¥3.78 | x |
| 2023-12-31 | CN¥3.40 | CN¥3.78 | x |
| 2024-12-31 | CN¥3.77 | CN¥3.78 | x |
| 2025-12-31 | CN¥3.67 | CN¥3.78 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Fuan Pharmaceutical Group Co utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.76%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.43%
- • Asset Turnover: 0.30x
- • Equity Multiplier: 1.32x
- Recent ROE (1.76%) is below the historical average (16.54%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 118.86% | 5.74% | 1.16x | 17.92x | CN¥4.91 Million |
| 2008 | 47.66% | 23.03% | 0.98x | 2.11x | CN¥36.11 Million |
| 2009 | 58.02% | 27.94% | 1.19x | 1.75x | CN¥75.04 Million |
| 2010 | 44.77% | 26.54% | 1.34x | 1.26x | CN¥95.63 Million |
| 2011 | 5.75% | 26.56% | 0.20x | 1.10x | CN¥-70.33 Million |
| 2012 | 5.20% | 21.07% | 0.23x | 1.06x | CN¥-81.59 Million |
| 2013 | 2.25% | 10.72% | 0.19x | 1.09x | CN¥-132.05 Million |
| 2014 | 2.68% | 10.19% | 0.24x | 1.07x | CN¥-124.98 Million |
| 2015 | 3.04% | 9.17% | 0.29x | 1.16x | CN¥-148.59 Million |
| 2016 | 5.60% | 17.11% | 0.29x | 1.11x | CN¥-174.40 Million |
| 2017 | 6.83% | 13.62% | 0.45x | 1.12x | CN¥-132.21 Million |
| 2018 | -9.75% | -13.49% | 0.62x | 1.16x | CN¥-729.34 Million |
| 2019 | 7.34% | 10.53% | 0.59x | 1.19x | CN¥-106.05 Million |
| 2020 | 5.11% | 8.84% | 0.40x | 1.46x | CN¥-200.65 Million |
| 2021 | -7.95% | -12.10% | 0.43x | 1.53x | CN¥-670.32 Million |
| 2022 | 5.19% | 8.45% | 0.41x | 1.49x | CN¥-189.90 Million |
| 2023 | 5.59% | 8.76% | 0.44x | 1.44x | CN¥-182.61 Million |
| 2024 | 6.37% | 11.70% | 0.40x | 1.36x | CN¥-159.75 Million |
| 2025 | 1.76% | 4.43% | 0.30x | 1.32x | CN¥-359.38 Million |
Industry Comparison
This section compares Fuan Pharmaceutical Group Co's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $8,448,219,723
- Average return on equity (ROE) among peers: 10.70%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Fuan Pharmaceutical Group Co (300194) | CN¥4.43 Billion | 118.86% | 0.27x | $658.07 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $2.14 Billion | 22.15% | 4.96x | $585.22 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.15 Billion | 3.98% | 1.16x | $407.31 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $897.61 Million | 10.79% | 0.14x | $4.27 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $14.94 Billion | 12.78% | 0.66x | $2.26 Billion |
| Wedge Industrial Co Ltd (000534) | $552.92 Million | 0.39% | 0.01x | $1.78 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $38.10 Billion | 10.98% | 0.30x | $13.33 Billion |
| Hainan Haiyao Co Ltd (000566) | $5.63 Billion | 2.92% | 0.71x | $875.19 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $141.91 Million | 11.01% | 0.32x | $311.17 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $2.05 Billion | 23.18% | 1.96x | $973.03 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $18.87 Billion | 8.83% | 0.08x | $3.07 Billion |
About Fuan Pharmaceutical Group Co
Fuan Pharmaceutical (Group) Co., Ltd., together with its subsidiaries, research and develops, produces, and sells chemical drugs in the People's Republic of China and internationally. It offers APIs; intermediates; and FDFs, such as anti-tumor, specialty drugs, antibiotics, as well as freeze-drying preparation for injection. The company was formerly known as Chongqing Fuan Pharmaceutical (Group) … Read more